Tag: first quarter

TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2026 and events which occurred subsequent to year end. (All figures are in Canadian dollars unless otherwise stated)

GEORGE TOWN, Cayman Islands, June 24, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, today announced that its Cayman Islands retail water utility, Cayman Water Company Limited, has received a new license from the Utility Regulation and Competition Office of the Cayman Islands (“OfReg”) to provide potable water service to customers in its licensed service areas on Grand Cayman.

Fiscal 2026 Net Income Expected Between $15 Million and $18 Million
Adjusted EBITDA Expected between $75 Million and $77 Million, an increase of 26% to 30%
First Day Program Revenues Estimated to Increase 27% to 28%
Board of Directors Declares Quarterly Dividend of $0.08 per Common Share

SUNNYVALE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Cerebras Systems Inc. (NASDAQ: CBRS), maker of the world’s fastest AI infrastructure, today announced financial results for the first quarter of fiscal year 2026, ended March 31, 2026.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GeneDx (WGS) To Contact Him Directly To Discuss Their Options

HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today reported financial and operational results for the first quarter ended March 31, 2026.

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.